NEW YORK – November 04, 2026 -- People with Parkinson's disease and their caregivers can now find an online hub, a practical guide and an interactive webinar explaining deep brain stimulation (DBS) at michaeljfox.org/dbs. The Michael J. Fox Foundation for Parkinson's Research (MJFF) and Medtronic plc built the materials together.
The hub covers how DBS works, its risks and life after surgery
The resources, collected in "The Live On with DBS Education Hub," explain how DBS works and its potential benefits and risks. They also cover preparing for surgery, adjusting to life with a DBS device, and the latest research advances. More programming is planned.
Medtronic is the premier partner of the initiative. MJFF says industry support lets it keep editorial oversight of the content while directing donor-raised dollars toward research.
An estimated 6 million people live with Parkinson's
The two organizations cite an estimated 6 million people worldwide with Parkinson's, a number expected to double by 2040. DBS has been used for nearly three decades, yet they say limited awareness and understanding still keep some patients from considering it.
Parkinson's is a progressive neurological disease that can affect movement, sleep, mood and cognition. Symptoms and progression vary from person to person. There is currently no cure or treatment proven to stop its progression.
DBS works like a pacemaker for the brain
DBS is often described as a cardiac pacemaker for the brain. A surgically implanted device sends electrical signals to specific brain areas that control movement. It is not appropriate for everyone. It is used alongside medication, and some patients may be able to reduce their medication use.
John L. Lipp, a writer and research advocate, has had DBS for five years. He also took part in the ADAPT-PD multi-center clinical trial. He says it has helped him stay active with family and friends. He stresses that choosing DBS is a personal decision and that people need clear information to weigh their options and talk with their care team.
Medtronic brings 30 years of DBS experience
Medtronic has supported DBS therapy for more than 30 years and has served more than 200,000 people with movement disorders and other conditions worldwide. In 2025, it introduced the world's first FDA-approved adaptive DBS system for Parkinson's disease.
Andrea Swain, president of Neuromodulation at Medtronic, said, "Innovation can only make a difference if people know it exists." Sohini Chowdhury, MJFF's chief program officer, said the materials are meant to help people explore what DBS may offer and keep them updated on scientific progress.
MJFF has funded more than $29 million in DBS research
Since 2000, MJFF has funded more than $29 million in DBS research for Parkinson's. That work includes exploring new brain targets and improving the technology to address more symptoms. The Foundation also funds the Registry for the Advancement of Deep Brain Stimulation Therapy in Parkinson's Disease (RAD-PD). The registry collects clinician and patient data on DBS outcomes, settings, side effects and access.